NasdaqCM:SSKN

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States and Asia. More Details


Snowflake Analysis

Flawless balance sheet and overvalued.


Similar Companies

Share Price & News

How has STRATA Skin Sciences's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: SSKN's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

0.7%

SSKN

0.6%

US Medical Equipment

0.08%

US Market


1 Year Return

-36.8%

SSKN

14.8%

US Medical Equipment

12.8%

US Market

Return vs Industry: SSKN underperformed the US Medical Equipment industry which returned 15.4% over the past year.

Return vs Market: SSKN underperformed the US Market which returned 13.6% over the past year.


Shareholder returns

SSKNIndustryMarket
7 Day0.7%0.6%0.08%
30 Day-15.8%1.2%-1.8%
90 Day3.0%11.5%7.2%
1 Year-36.8%-36.8%15.8%14.8%15.3%12.8%
3 Year-23.2%-23.2%72.3%67.9%39.2%29.9%
5 Year-74.7%-74.7%148.2%129.3%88.3%67.1%

Price Volatility Vs. Market

How volatile is STRATA Skin Sciences's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is STRATA Skin Sciences undervalued compared to its fair value and its price relative to the market?

1.75x

Price to Book (PB) ratio


Share Price vs. Fair Value

Below Fair Value: SSKN ($1.39) is trading above our estimate of fair value ($0.49)

Significantly Below Fair Value: SSKN is trading above our estimate of fair value.


Price To Earnings Ratio

PE vs Industry: SSKN is unprofitable, so we can't compare its PE Ratio to the US Medical Equipment industry average.

PE vs Market: SSKN is unprofitable, so we can't compare its PE Ratio to the US market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate SSKN's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: SSKN is good value based on its PB Ratio (1.8x) compared to the US Medical Equipment industry average (3.9x).


Next Steps

Future Growth

How is STRATA Skin Sciences forecast to perform in the next 1 to 3 years based on estimates from 3 analysts?

33.9%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: SSKN is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: SSKN is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: SSKN is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: SSKN's revenue (11.6% per year) is forecast to grow faster than the US market (9.7% per year).

High Growth Revenue: SSKN's revenue (11.6% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if SSKN's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has STRATA Skin Sciences performed over the past 5 years?

34.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: SSKN is currently unprofitable.

Growing Profit Margin: SSKN is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: SSKN is unprofitable, but has reduced losses over the past 5 years at a rate of 34.8% per year.

Accelerating Growth: Unable to compare SSKN's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: SSKN is unprofitable, making it difficult to compare its past year earnings growth to the Medical Equipment industry (-0.2%).


Return on Equity

High ROE: SSKN has a negative Return on Equity (-15.27%), as it is currently unprofitable.


Next Steps

Financial Health

How is STRATA Skin Sciences's financial position?


Financial Position Analysis

Short Term Liabilities: SSKN's short term assets ($23.9M) exceed its short term liabilities ($16.6M).

Long Term Liabilities: SSKN's short term assets ($23.9M) exceed its long term liabilities ($2.8M).


Debt to Equity History and Analysis

Debt Level: SSKN's debt to equity ratio (36.6%) is considered satisfactory.

Reducing Debt: SSKN's debt to equity ratio has reduced from 65.6% to 36.6% over the past 5 years.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: Whilst unprofitable SSKN has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.

Forecast Cash Runway: SSKN is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 63.2% per year.


Next Steps

Dividend

What is STRATA Skin Sciences's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate SSKN's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate SSKN's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if SSKN's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if SSKN's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of SSKN's dividend in 3 years as they are not forecast to pay a notable one for the US market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.8yrs

Average management tenure


CEO

Dolev Rafaeli (56 yo)

2.42yrs

Tenure

US$1,167,630

Compensation

Dr. Dolev Rafaeli, Ph.D., has been Chief Executive Officer and Director of Strata Skin Sciences, Inc. since May 29, 2018. Dr. Rafaeli served as President and Interim Chief Executive Officer of Strata Skin ...


CEO Compensation Analysis

Compensation vs Market: Dolev's total compensation ($USD1.17M) is above average for companies of similar size in the US market ($USD595.72K).

Compensation vs Earnings: Dolev's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Dolev Rafaeli
CEO, President & Director2.42yrsUS$1.17m2.76%
$ 1.3m
Matthew Hill
VP & CFO2.33yrsUS$638.54k0.030%
$ 13.9k
Uri Geiger
Chairman of the Board2.33yrsUS$40.00kno data
Jay Sturm
General Counsel & Corporate Secretaryno datano datano data
Keith Simeone
Vice President of Salesno datano datano data
Darrell Rigel
Chief Medical Advisor6.92yrsno datano data
Shmuel Gov
Executive VP & GMno datano datano data
Nikolai Kabelev
Vice President of Research & Development12.67yrsUS$370.90kno data
Michael Stewart
Independent Consultant3.83yrsUS$732.90kno data

3.8yrs

Average Tenure

56yo

Average Age

Experienced Management: SSKN's management team is considered experienced (3.8 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Dolev Rafaeli
CEO, President & Director2.42yrsUS$1.17m2.76%
$ 1.3m
Uri Geiger
Chairman of the Board2.33yrsUS$40.00kno data
Daniel Lufkin
Director Emeritus10.42yrsUS$28.62kno data
Samuel Navarro
Independent Director6.5yrsUS$70.00k0.059%
$ 27.8k
Nachum Shamir
Independent Director2.33yrsUS$80.00k0.17%
$ 80.4k
R. Anderson
Member of Scientific Advisory Board3.33yrsUS$10.25kno data
LuAnn Via
Independent Director8.42yrsUS$75.00k0.12%
$ 56.4k
Shmuel Rubinstein
Independent Director2.33yrsUS$80.00k0.033%
$ 15.7k

2.8yrs

Average Tenure

66yo

Average Age

Experienced Board: SSKN's board of directors are not considered experienced ( 2.8 years average tenure), which suggests a new board.


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Company Information

STRATA Skin Sciences, Inc.'s company bio, employee growth, exchange listings and data sources


Key Information

  • Name: STRATA Skin Sciences, Inc.
  • Ticker: SSKN
  • Exchange: NasdaqCM
  • Founded: 1989
  • Industry: Health Care Equipment
  • Sector: Healthcare
  • Market Cap: US$46.919m
  • Shares outstanding: 33.75m
  • Website: https://www.strataskinsciences.com

Number of Employees


Location

  • STRATA Skin Sciences, Inc.
  • 5 Walnut Grove Drive
  • Suite 140
  • Horsham
  • Pennsylvania
  • 19044
  • United States

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
SSKNNasdaqCM (Nasdaq Capital Market)YesCommon StockUSUSDOct 2005
E2OMDB (Deutsche Boerse AG)YesCommon StockDEEUROct 2005

Biography

STRATA Skin Sciences, Inc., a medical technology company, develops, commercializes, and markets products for the treatment of dermatologic conditions in the United States and Asia. The company operates in ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/09/21 06:09
End of Day Share Price2020/09/18 00:00
Earnings2020/06/30
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.